Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Australia / NCT01742403
Active, not recruiting Not applicable

Continuous Monitoring of Prostate Position During Radiotherapy

NCT01742403 · tracked via the Priya Life Science Australia tracker
Sponsor
Royal North Shore Hospital
Phase
Not applicable
Started
2013-01-01
Last updated
2026-02-06

Condition(s) studied

Prostate Cancer

Investigational drug(s) / intervention(s)

R/T gating kV intrafraction monitoring

R/T gating kV intrafraction monitoring: This is a Phase I Pilot study to assess the feasibility of implementing prostate radiotherapy gating using kV intrafraction monitoring.

Study summary

This study is investigating measurement of prostate motion during radiotherapy using the implanted gold markers. If motion is greater than 3mm then the beam will be stopped and position corrected (gating).

Eligibility

Sex
MALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients undergoing definitive external beam radiotherapy; * Histological proven prostate adenocarcinoma * Prostate Specific Antigen (PSA),within 3 months prior to enrolment * Patient must be able to have gold fiducial markers placed in the prostate (if on anticoagulants, must be approved for procedure by Cardiologist) * Artificial hips * Lymph Node irradiation * Patient Dimensions \>40cms * ECOG 0-2 * Ability to understand and willingness to sign informed consent form. Exclusion Criteria: * Altered fractionation * Fiducials must be no less than 1cm apart

Primary outcome measure(s)

  • Feasibility of KIM techique — 10 years
    Technique will be determined as feasible if 90% of treatment fractions are successfully segmented in real time.

Trial sites (1)

FacilityCityRegionStatus
Department of Radiation Oncology, Northern Sydney Cancer Centre St Leonards New South Wales

More Royal North Shore Hospital trials in Australia

Pelvis Adaptive Radiotherapy (ART) Recruiting
Positioning of Esketamine Treatment in the Real-world Management of Depression Recruiting
The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab Recruiting
Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking Active, not recruiting
De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE) Recruiting

Other trials for the same condition

PSMA PET Combined With MRI for the Detection of PCa Recruiting
LTFU for All Cell and Gene Therapy Studies Starting soon
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation Recruiting
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer Active, not recruiting
Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01742403 on ClinicalTrials.gov ↗ ← All trials in Australia